1. Home
  2. IDYA vs DEI Comparison

IDYA vs DEI Comparison

Compare IDYA & DEI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IDYA
  • DEI
  • Stock Information
  • Founded
  • IDYA 2015
  • DEI 1971
  • Country
  • IDYA United States
  • DEI United States
  • Employees
  • IDYA N/A
  • DEI N/A
  • Industry
  • IDYA Biotechnology: Pharmaceutical Preparations
  • DEI Real Estate Investment Trusts
  • Sector
  • IDYA Health Care
  • DEI Real Estate
  • Exchange
  • IDYA Nasdaq
  • DEI Nasdaq
  • Market Cap
  • IDYA 2.3B
  • DEI 2.6B
  • IPO Year
  • IDYA 2019
  • DEI 2006
  • Fundamental
  • Price
  • IDYA $31.60
  • DEI $12.73
  • Analyst Decision
  • IDYA Buy
  • DEI Hold
  • Analyst Count
  • IDYA 17
  • DEI 8
  • Target Price
  • IDYA $48.20
  • DEI $17.86
  • AVG Volume (30 Days)
  • IDYA 1.3M
  • DEI 1.9M
  • Earning Date
  • IDYA 11-04-2025
  • DEI 11-04-2025
  • Dividend Yield
  • IDYA N/A
  • DEI 5.97%
  • EPS Growth
  • IDYA N/A
  • DEI N/A
  • EPS
  • IDYA N/A
  • DEI 0.22
  • Revenue
  • IDYA $7,000,000.00
  • DEI $1,001,173,000.00
  • Revenue This Year
  • IDYA $90.17
  • DEI $2.92
  • Revenue Next Year
  • IDYA $219.42
  • DEI $1.96
  • P/E Ratio
  • IDYA N/A
  • DEI $58.68
  • Revenue Growth
  • IDYA N/A
  • DEI 3.24
  • 52 Week Low
  • IDYA $13.45
  • DEI $12.39
  • 52 Week High
  • IDYA $33.64
  • DEI $20.50
  • Technical
  • Relative Strength Index (RSI)
  • IDYA 63.75
  • DEI 22.97
  • Support Level
  • IDYA $28.17
  • DEI $12.59
  • Resistance Level
  • IDYA $33.64
  • DEI $13.67
  • Average True Range (ATR)
  • IDYA 1.70
  • DEI 0.32
  • MACD
  • IDYA 0.33
  • DEI -0.05
  • Stochastic Oscillator
  • IDYA 72.58
  • DEI 10.25

About IDYA IDEAYA Biosciences Inc.

IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.

About DEI Douglas Emmett Inc.

Douglas Emmett Inc is an integrated, self-administered, and self-managed REIT. It is an owner and operator of office and multifamily properties located in coastal submarkets in Los Angeles and Honolulu. The group focuses on owning, acquiring, developing, and managing a substantial market share of office properties and multifamily communities in neighborhoods with supply constraints, high-end executive housing, and key lifestyle amenities. Its properties are located in the Beverly Hills, Brentwood, Burbank, Century City, Olympic Corridor, Santa Monica, Sherman Oaks/Encino, Warner Center/Woodland Hills and Westwood submarkets of Los Angeles County, California, and in Honolulu, Hawaii. It has two business segments, the office segment and the multifamily segment.

Share on Social Networks: